Effect of Isoniazid Intake on Ethionamide Pharmacokinetics and Target Attainment in Multidrug-Resistant Tuberculosis Patients-Reference-Cited by-同舟云学术

Effect of Isoniazid Intake on Ethionamide Pharmacokinetics and Target Attainment in Multidrug-Resistant Tuberculosis Patients

Published:2021-09-17 Issue:10 Volume:65 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Chirehwa Maxwell T.¹^ORCID,Court Richard¹,de Kock Mariana²,Wiesner Lubbe¹^ORCID,de Vries Nihal³,Harding Joseph⁴,Gumbo Tawanda⁵^ORCID,Maartens Gary¹⁶^ORCID,Warren Rob²,Denti Paolo¹^ORCID,McIlleron Helen¹⁶^ORCID

Affiliation:

1. Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa

2. NRF-DSI Centre of Excellence in Biomedical Tuberculosis Research, SAMRC Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Stellenbosch University, Cape Town, South Africa

3. Brooklyn Chest Hospital, Cape Town, South Africa

4. DP Marais Hospital, Cape Town, South Africa

5. Quantitative Preclinical and Clinical Sciences Department, Praedicare Inc., Dallas, Texas, USA

6. Wellcome Centre for Infectious Diseases Research in Africa (CIDRI-Africa), Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa

Abstract

Ethionamide is recommended as part of regimens to treat multidrug-resistant and rifampicin-resistant tuberculosis. This study was conducted to (i) describe the distribution of ethionamide MICs, (ii) describe the pharmacokinetics of ethionamide, and (iii) determine the probability of attaining target area under the concentration-time curve from 0 to 24 h (AUC 0–24 )/MIC values associated with suppression of resistant subpopulation and microbial kill.

Funder

HHS | NIH | National Institute of Allergy and Infectious Diseases

Wellcome

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00278-21

Reference33 articles.

1. World Health Organization. 2020. WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment. World Health Organization, Geneva, Switzerland.

2. Treatment and Outcome Analysis of 205 Patients with Multidrug-resistant Tuberculosis

3. Court R Center C Chirehwa M Wiesner L Denti P de Vries N Harding J Gumbo T Maartens G McIlleron H. 2020. Risk factors for neurotoxicity including cycloserine exposure in patients on treatment for multidrug-resistant tuberculosis p EP09-176-21. In The 51st Union World Conference on Lung Health. EP09-176-21

4. Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative;Nathanson E;Int J Tuber Lung Dis,2004

5. High-level resistance to isoniazid and ethionamide in multidrug-resistant Mycobacterium tuberculosis of the Lisboa family is associated with inhA double mutations

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacometrics in tuberculosis: progress and opportunities;International Journal of Antimicrobial Agents;2022-09

2. Pharmacokinetics of standard versus high-dose isoniazid for treatment of multidrug-resistant tuberculosis;Journal of Antimicrobial Chemotherapy;2022-06-09

3. Phosphatidylcholine (18:0/20:4), a potential biomarker to predict ethionamide‐induced hepatic steatosis in rats;Journal of Applied Toxicology;2022-03-29

4. Molecular Determinants of Ethionamide Resistance in Clinical Isolates of Mycobacterium tuberculosis;Antibiotics;2022-01-20